Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Mingjun Wang
  • Guru Sonpavde
  • Helen Y. Wang
  • Rong-Fu Wang
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7100-8



NY-ESO-1 is a tumor-specific antigen of the cancer/testis antigen family and is encoded by a gene located at Xq28. It is composed of 180 amino acids with a molecular weight of 18 kD. NY-ESO-1 is strongly expressed in various types of cancers, but not in normal somatic tissues or cells except normal testes, ovary, and placenta.


NY-ESO-1 was first identified as a tumor antigen in 1997 by Chen et al. (1997a) using sera from a patient with esophageal squamous cell carcinoma after serological analysis of recombinant cDNA expression libraries (SEREX). Shortly afterwards, Jäger et al. (1998) and Wang et al. (1998a) independently reported that NY-ESO-1 could be recognized by T cells from melanoma patients. Thus, NY-ESO-1 can induce both antibody and T-cell responses in the...


Esophageal Squamous Cell Carcinoma Synovial Cell Sarcoma Strong Immunogenicity Antigen Family Beneficial Clinical Outcome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.



We would like to thank Drs. Adebusola Alagbala Ajibade and Christopher Loo for manuscript editing.


  1. Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100:2014–2021CrossRefPubMedGoogle Scholar
  2. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337CrossRefPubMedGoogle Scholar
  3. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997a) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94:1914–1918CrossRefPubMedPubMedCentralGoogle Scholar
  4. Chen YT, Boyer AD, Viars CS, Tsang S, Old LJ, Arden KC (1997b) Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet 79:237–240CrossRefPubMedGoogle Scholar
  5. Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, Knuth A, Chen YT, Old LJ (2006) NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 95:1–30CrossRefPubMedGoogle Scholar
  6. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270CrossRefPubMedPubMedCentralGoogle Scholar
  7. Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A (2000) Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 191:625–630CrossRefPubMedPubMedCentralGoogle Scholar
  8. Kennedy R, Celis E (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222:129–144CrossRefPubMedGoogle Scholar
  9. Liu Y, Tian X, Leitner WW, Aldridge ME, Zheng J, Yu Z, Restifo NP, Weiss R, Scheiblhofer S, Xie C, Sun R, Cheng G, Zeng G (2011) Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo. J Biol Chem 286:37077–37084CrossRefPubMedPubMedCentralGoogle Scholar
  10. Old LJ (2008) Cancer vaccines: an overview. Cancer Immun 8(Suppl 1):1PubMedGoogle Scholar
  11. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917–924CrossRefPubMedPubMedCentralGoogle Scholar
  12. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA (1998a) A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 161:3598–3606PubMedGoogle Scholar
  13. Wang RF, Wang X, Johnston SL, Zeng G, Robbins PF, Rosenberg SA (1998b) Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens. Cancer Res 58:3519–3525PubMedGoogle Scholar
  14. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD (2011) CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother: CII 60:1137–1146CrossRefPubMedPubMedCentralGoogle Scholar
  15. Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF (2000) Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 165:1153–1159CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Mingjun Wang
    • 1
  • Guru Sonpavde
    • 2
  • Helen Y. Wang
    • 1
  • Rong-Fu Wang
    • 1
  1. 1.Center for Inflammation and EpigeneticsHouston Methodist Research InstituteHoustonUSA
  2. 2.Texas Oncology and Veterans Affairs Medical Center and the Baylor College of MedicineHoustonUSA